News from REMEDY

Let's get LinkedIn up and running for the REMEDY Center!

The driver to increase in size and reach is people liking and sharing. If you have the opportunity to click into LinkedIn, you can share the matter in English. There is also a Norwegian version that can be shared.

The health sector is responsible for large greenhouse gas emissions. Now two leading research environments in Norway are taking an international initiative to calculate the climate footprint in advance of medical treatments. The goal is to offer healthcare services that are best for both the patient and the planet. These ambitions have recently been published in the highest ranked medical journal internationally, The New England Journal of Medicine ^[1]. 

The doctoral work shows a connection between the patient's immune response and treatment effect in inflammatory diseases of the joints and intestines. The research has contributed to greater understanding of how the immune system affects the effect of biological medicines and COVID-19 vaccines in people with such diseases.

Join the MAGIC Evidence Ecosystem Foundation for the Conference on Evidence-Based Medicine and AI to explore the implications for healthcare policy and practice in Norway.

- We are thrilled to invite you to register for an exciting and insightful conference exploring the synergy between Evidence-Based Medicine (EBM) and Artificial Intelligence (AI), focusing on the implications for healthcare policy and practice in Norway, says Per Olav Vandvik, CEO of MAGIC.

The event is free, and we have room for 150 good colleagues (first come, first served) at Deichman in Bjørvika.

In addition, we broadcast digitally, so that everyone can experience the highlights from EULAR. Here you will find the registration form!

Green Congress will be held for the fourth time, 21 June 2024 at Deichman Bjørvika. True to tradition, the event opens with an environmental lecture. This year we have been lucky enough to bring CICERO researcher Bob van Oort with us.

Professor Nina Østerås, head of the Unit for Health Services Research, gave an abstract presentation about the SAMBA study's eight-year link to the prosthesis register. 

In Marthe Kirkesæther Brun's doctoral work lies the key to preventing disease flare-ups in individuals with chronic inflammatory disease: The dosage of the biological drug infliximab should be adjusted over time, based on measurements of the drug's concentration in the blood.

The point-giving course in user participation in medical and healthcare research was held at the Eitri Health Incubator at Haukeland Hospital.

From REMEDY, adviser Marianne Skaar has participated in the program committee and as a facilitator.